Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

NCT02301039 is registered in ClinicalTrials.gov with Sarcoma Alliance for Research through Collaboration as lead sponsor.

NCT NCT02301039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02301039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2015
Completion date
July 1, 2020
Enrollment
144 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bone sarcoma, soft tissue sarcoma